Group 1 - Hendi Pharmaceutical experienced a 5% increase in stock price, reaching 13.65 CNY per share, with a trading volume of 136 million CNY and a turnover rate of 2.41%, resulting in a total market capitalization of 5.7 billion CNY [1] - Hendi Pharmaceutical, established on December 29, 1995, is located in Jingmen City, Hubei Province, and was listed on December 22, 2021. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main revenue composition of Hendi Pharmaceutical includes non-steroidal anti-inflammatory drugs (68.06%), cardiovascular products (16.08%), other products (8.86%), and anti-tumor drugs (6.99%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under Dongfang Fund has a significant position in Hendi Pharmaceutical. The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) held 11,600 shares in the third quarter, accounting for 0.43% of the fund's net value, ranking as the sixth largest holding [2] - The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) was established on February 22, 2019, with a latest scale of 28.7844 million CNY. The fund has achieved a year-to-date return of 10.05%, ranking 895 out of 8,836 in its category, and a one-year return of 56.94%, ranking 1,801 out of 8,091 [2] - The fund manager, Wang Huaixun, has been in position for 3 years and 243 days, with the total asset scale of the fund at 799 million CNY. During his tenure, the best fund return was 70.43%, while the worst was -0.06% [2]
亨迪药业股价涨5%，东方基金旗下1只基金重仓，持有1.16万股浮盈赚取7517.25元